In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas

Neuro-Oncology

Volumn 11, Issue 2, 2009, Pages 102-108

  Uzzaman, Mahmud ^a   Keller, Gordon ^a   Germano, Isabelle M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocytes; Embryonic stem cell; Gene therapy; Malignant glioma; TRAIL

Indexed keywords

DEATH RECEPTOR 4; DOXYCYCLINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CONTROLLED STUDY; EMBRYONIC STEM CELL; FEMALE; GENE DELIVERY SYSTEM; GENE INDUCTION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; ASTROCYTES; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; EMBRYONIC STEM CELLS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIOMA; HUMANS; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ENGINEERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65949102292     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-056     Document Type: Article

References (40)

1. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 1998;40:151-160.
2. Chiocca EA, Aghi M, Fulci G. Viral therapy for glioblastoma. Cancer J. 2003;9:167-179.
3. Rainov NG, Kramm CM. Recombinant retroviruses for treatment of malignant brain tumors. Int Rev Neurobiol. 2003;55:185-203.
4. Hampl JA, Camp SM, Mydlarz WK, et al. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Hum Gene Ther. 2003;14:611-626.
5. Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes sim- plex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neuroon- col. 2003;65(3):279-289.
6. Chiocca EA. Oncolytic viruses. Nat Rev Cancer. 2002;2:938-950.
7. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experi- mental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-856.
8. Fulci G, Dmitrieva N, Gianni D, et al. Depletion of peripheral mac- rophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 2007;67:9398-9406.
9. Lee J, Elkhaloun AG, Messina SA, et al. Cellular and genetic character- ization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector. Cancer Res. 2003;63:8877-8889.
10. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther- apy. 2004;11:1155-1164.
11. Srivastava AS, Sheaouda S, Mishra R, Carrier E. Transplanted embry- onic stem cells successfully survive, proliferate, and migrate to dam- aged regions of the mouse brain. Stem Cells. 2006;24:1689-1694.
12. Heese O, Disko A, Zirkel D, Westphal-Lazmus M. Neural stem cell migration toward gliomas in vitro. Neuro-Oncology. 2005;7:476-484.
13. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab. 2003;23:137-149.
14. Eriksson C, Ericson C, Gates MA. Long-term, EGF-stimulated cultures of attached GFAP-positive cells derived from the embryonic mouse lateral ganglionic eminence: in vitro and transplantation studies. Exp Neurol. 2000;164:184-199.
15. Selkirk SM, Greenberg SJ, Plunkett RJ, Barone TA, Lis A, Spence PO. Syngeneic central nervous system transplantation of genetically trans- duced mature, adult astrocytes. Gene Ther. 2002;9:432-443.
16. Jandial R, Singec I, Ames CP, Snyder EY. Genetic modification of neu- ral stem cells. Mol Ther. 2008;16(3):450-457.
17. Shih CC, Fu L, Zhu L, Huang Y, Lee TD, Forman SJ. Derivation of neu- ral stem cells from mesenchymal stem cells: evidence for a bipotential stem cell population. Stem Cells Dev. 2008 (online April 21).
18. Benveniste RJ, Keller G, Germano IM. Embryonic stem cell-derived astrocytes expressing drug-inducible transgenes: differentiation and transplantation into the mouse brain. J Neurosurg. 2005;103:115-123.
19. Grataroli R, Vindrieux D, Selva J, Felsenheld C, Ruffion A, Decaussin M. Characterization of tumor necrosis factor alpha-related apoptosis inducing ligand and its receptors in the adult human testis. Mol Hum Reprod. 2004;10:123-128.
20. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis inducing ligand (TRAIL) gene. Cancer Res. 2001;61:3330-3338.
21. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitiza- tion to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther. 2007;6:2103-2112.
22. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the dis- position of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinet- ics, and safety. J Pharmacol Exp Ther. 2001;299:31-38.
23. Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res. 2004;64(19):6858-6862.
24. Linninger AA, Somayaji MR, Mekarski M, Zhang L. Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol. 2008;250(1):125-138.
25. Laird DJ, von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth, and disease. Cell. 2008;22:132(4):612-630.
26. Germano IM, Uzzaman M, Benveniste RJ, Zaurova M, Keller G. Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg. 2006;105:88-95.
27. Uzzaman M, Benveniste RJ, Keller G, Germano IM. Embryonic stem cell-derived astrocytes: a novel approach as a gene therapy vector for brain tumors. Neurosurg Focus. 2005;19(3):E6.
28. Poon Poon, RY. PKH fluorescent cell linker dyes. In Diamond RA, DeMaggio S, eds. Living color: flow cytometry and cell sorting proto- cols. 2002:302-352.
29. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer- specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A. 2005;102(39):14034-14039.
30. Ehtesham M, Kabos P, Gutierrez MA, et al. Induction of glioblastoma apop- tosis using neural stem cell-mediated delivery of tumor necrosis factor- related apoptosis inducing ligand. Cancer Res. 2002;62:7170-7174.
31. Lawler SE, Peruzzi PP, Chiocca EA. Genetic strategies for brain tumor therapy. Cancer Gene Therapy. 2006;13:225-233.
32. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21:2508-2518.
33. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 2005;19:1129-1155.
34. Uzzaman M, Keller G, Germano IM. Enhanced pro-apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on temozolomide-resistant glioma cells. J Neurosurg. 2007;106:646-651.
35. Badie B, Goh CS, Klaver J, Herweijer H, Boothman DA. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther. 1999;6(2):155-162.
36. Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clini- cal implications. Drug Resist Update. 2004;7:139-156.
37. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett. 2003;139(2-3):89-97.
38. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66-75.
39. Kyritsis AP, Tachmazoglou F, Rao JS, Puduvalli VK. Temozolomide and resistant glioma cells. J Neurosurg. 2008;108:197.
40. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis. 2005;10(1):233-243.